Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.67 |
| ▸ | CASR | P41180 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA7 | P43166 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.57 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615348 | 0.89 | KDR (0.85) | KDRTRPV1CASRCA1CA2 | |
| SCHEMBL16628086 | 0.88 | KDR (0.68) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL16628038 | 0.87 | LMNA (0.61) | KDRTRPV1CASRCA1CA2 | |
| SCHEMBL118026 | 0.85 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL29364392 | 0.85 | KDR (1.00) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL19678074 | 0.85 | SAE1 (0.56) | KDRTRPV1CA1CA2CA9 | |
| SCHEMBL3790500 | 0.84 | KDR (0.64) | KDRTRPV1CASRCA1CA2 | |
| SCHEMBL12310641 | 0.84 | KDR (0.76) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL19668016 | 0.83 | KDR (0.74) | KDRTRPV1CASRCA1CA2 | |
| Cloflucarban SCHEMBL27537485 | 0.82 | KDR (0.88) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| CN-109890804-A | Compounds containing urea moieties and derivatives thereof as antibacterial agents | 慕尼黑工业大学 | 2019-06-14 | — | — | CN | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UMPS, UNG, UFM1 | KDR 3399/4885TRPV1 3838/4885CASR 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.